Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 314Terminated 77Recruiting 61Active not recruiting 36Withdrawn 22Unknown 21Not yet recruiting 4Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 73Breast Neoplasms 70Colorectal Neoplasms 39Prostatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 25Stomach Neoplasms 20Carcinoma, Hepatocellular 20Uterine Cervical Neoplasms 19Pancreatic Neoplasms 15Anxiety Disorders 15Leukemia, Myeloid, Acute 14Hematologic Neoplasms 13Colonic Neoplasms 13Brain Neoplasms 13Urinary Bladder Neoplasms 12Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Head and Neck Neoplasms 11Esophageal Neoplasms 10Diabetes Mellitus 10Ovarian Neoplasms 9Melanoma 9Liver Neoplasms 9Sarcoma 8Rectal Neoplasms 8Pulmonary Disease, Chronic Obstructive 8Multiple Myeloma 8Esophageal Squamous Cell Carcinoma 8Disease 8

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Leukemia, Myelomonocytic, Chronic × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡